Classification of 5-HT1A receptor agonists and antagonists using GA-SVM method

被引:4
作者
Zhu, Xue-lian [1 ]
Cai, Hai-yan [1 ]
Xu, Zhi-jian [1 ]
Wang, Yong [1 ]
Wang, He-yao [1 ]
Zhang, Ao [1 ]
Zhu, Wei-liang [1 ]
机构
[1] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
基金
中国国家自然科学基金;
关键词
5-HT1A receptor; support vector machine; genetic algorithm; agonist; antagonists; VIVO PHARMACOLOGICAL EVALUATION; SEROTONIN TRANSPORTER AFFINITY; IN-VITRO; DUAL; 5-HT1A; REUPTAKE INHIBITORS; LIGANDS; POTENT; DERIVATIVES; DISCOVERY; ANALOGS;
D O I
10.1038/aps.2011.112
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Aim: To construct a reliable computational model for the classification of agonists and antagonists of 5-HT1A receptor. Methods: Support vector machine (SVM), a well-known machine learning method, was employed to build a prediction model, and genetic algorithm (GA) was used to select the most relevant descriptors and to optimize two important parameters, C and r of the SVM model. The overall dataset used in this study comprised 284 ligands of the 5-HT1A receptor with diverse structures reported in the literatures. Results: A SVM model was successfully developed that could be used to predict the probability of a ligand being an agonist or antagonist of the 5-HT1A receptor. The predictive accuracy for training and test sets was 0.942 and 0.865, respectively. For compounds with probability estimate higher than 0.7, the predictive accuracy of the model for training and test sets was 0.954 and 0.927, respectively. To further validate our model, the receiver operating characteristic (ROC) curve was plotted, and the Area-Under-the-ROC-Curve (AUC) value was calculated to be 0.883 for training set and 0.906 for test set. Conclusion: A reliable SVM model was successfully developed that could effectively distinguish agonists and antagonists among the ligands of the 5-HT1A receptor. To our knowledge, this is the first effort for the classification of 5-HT1A receptor agonists and antagonists based on a diverse dataset. This method may be used to classify the ligands of other members of the GPCR family.
引用
收藏
页码:1424 / 1430
页数:7
相关论文
共 63 条
  • [1] Discovery of Innovative Small Molecule Therapeutics
    Abou-Gharbia, Magid
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (01) : 2 - 9
  • [2] [Anonymous], DISC STUD MOD ENV RE
  • [3] 3,4-dihydro-2H-benzoxazinones are 5-HT1A receptor antagonists with potent 5-HT reuptake inhibitory activity
    Atkinson, PJ
    Bromidge, SM
    Duxon, MS
    Gaster, LM
    Hadley, MS
    Hammond, B
    Johnson, CN
    Middlemiss, DN
    North, SE
    Price, GW
    Rami, HK
    Riley, GJ
    Scott, CM
    Shaw, TE
    Starr, KR
    Stemp, G
    Thewlis, KM
    Thomas, DR
    Thompson, M
    Vong, AKK
    Watson, JM
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (03) : 737 - 741
  • [4] An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression
    Becker, Oren M.
    Dhanoa, Dale S.
    Marantz, Yael
    Chen, Dongli
    Shacham, Sharon
    Cheruku, Srinivasa
    Heifetz, Alexander
    Mohanty, Pradyumna
    Fichman, Merav
    Sharadendu, Anurag
    Nudelman, Raphael
    Kauffman, Michael
    Noiman, Silvia
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (11) : 3116 - 3135
  • [5] G-protein coupled receptors: Models, mutagenesis, and drug design
    Bikker, JA
    Trumpp-Kallmeyer, S
    Humblet, C
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (16) : 2911 - 2927
  • [6] Structure-intrinsic activity relationship studies in the group of 1-imido/amido substituted 4-(4-arylpiperazin-1-yl) cyclohexane derivatives;: new, potent 5-HT1A receptor agents with anxiolytic-like activity
    Bojarski, AJ
    Paluchowska, MH
    Duszynska, B
    Bugno, R
    Klodzinska, A
    Tatarczynska, E
    Chojnacka-Wójcik, E
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (05) : 1391 - 1402
  • [7] 1-aryl-4-(4-succinimidobutyl)piperazines and their conformationally constrained analogues:: synthesis, binding to serotonin (5-HT1A,5-HT2A,5-HT7), α1-adrenergic, and dopaminergic D2 receptors, and in vivo 5-HT1A functional characteristics
    Bojarski, AJ
    Paluchowska, MH
    Duszynska, B
    Klodzinska, A
    Tatarczynska, E
    Chojnacka-Wójcik, E
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (06) : 2293 - 2303
  • [8] Pharmacophore models for metabotropic 5-HT receptor ligands
    Bojarski, Andrzej J.
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (18) : 2005 - 2026
  • [9] 6-[2-(4-aryl-1-piperazinyl)ethyl]-2H-1,4-benzoxazin-3(4H)-ones:: Dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors
    Bromidge, Steven M.
    Bertani, Barbara
    Borriello, Manuela
    Faedo, Stefania
    Gordon, Laurie J.
    Granci, Enrica
    Hill, Matthew
    Marshall, Howard R.
    Stasi, Luigi P.
    Zucchelli, Valeria
    Merlo, Giancarlo
    Vesentini, Alessia
    Watson, Jeannette M.
    Zonzini, Laura
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (20) : 5653 - 5656
  • [10] Synthesis and 5-HT1A, 5-HT2A receptor activity of new β-tetralonohydantoins
    Byrtus, H
    Pawlowski, M
    Czopek, A
    Bojarski, AJ
    Duszyanska, B
    Nowak, G
    Klodzinska, A
    Tatarczynska, E
    Wesolowska, A
    Chojnacka-Wójcik, E
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2005, 40 (08) : 820 - 829